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Urinary kallikrein and salt sensitivity in essential hypertensive males.
A strong influence of urinary kallikrein excretion on the salt sensitivity of
blood pressure has been recently suggested in normotensive patients. To
evaluate the relationship between kallikrein and salt sensitivity in essential
hypertension, active kallikrein excretion, plasma renin activity, atrial
natriuretic peptide and aldosterone levels were evaluated in 37 male
hypertensives (mean age 43.3 4.7 years) after two weeks on a normal
NaCI diet (120 mmol NaCI per day). After kallikrein determination, salt
sensitivity was assessed in a randomized cross-over double-blind fashion
by evaluating the blood pressure response to a high (240 mmol NaCI per
day for two weeks) and a low (40 mmol NaCI per day for 2 weeks) NaCI
intake. Blood pressure changes were evaluated considering as baseline
blood pressure the measurement taken at the end of the 2 weeks under
normal NaCI intake. Patients were classified as salt sensitive when a
diastolic blood pressure change of 10 mm Hg or more occurred after both
periods of low and high NaCI intake. At the end of the assessment of salt
sensitivity, 19 hypertensive patients (mean age 43.0 4.6 years) were
salt sensitive while 18 (mean age 435 4.7years) were classified as salt
resistant. The urinary excretion of active kallikrein was significantly lower
(P c 0.0001) in salt sensitive (0.51 0.36 U/24 hr) than in salt resistant
patients (1.28 0.48 U/24 hr). Also, plasma atrial natriuretic peptide
levels were higher in salt sensitive than in salt resistant hypertensives (P <
0.02), and a significant correlation between urinary kallikrein and plasma
atrial natriuretie peptide was demonstrated in salt sensitive hypertensives(r =
—0.691, P < 0.001). These findings indicate a strong relationship
between active kallikrein excretion and blood pressure sensitivity to NaCI
intake in human essential hypertension, and suggest the increase in plasma
ANP levels, often described in hypertensives, as a compensatory mecha-
nism to an impaired renal sodium excretory function.
The blood pressure response to changes in dietary NaC1 intake
is continuously distributed in both normotensives and hyperten-
sives, enabling the recognition of two overlapping but clearly
identifiable subgroups: the salt sensitive and the salt resistant ones
[reviewed in 1 and 2].
Salt sensitivity seems to be more frequent in hypertensives
characterized as being older, obese and having higher initial blood
pressure [2, 3]. Furthermore, salt sensitivity is particularly com-
mon in black hypertensives [2].
The mechanisms responsible for the salt sensitivity of blood
pressure are still unclear, limiting the efficacy of indiscriminate
salt restriction as a non-pharmacological antihypertensive ther-
apy. Therefore, several researchers attempted to identify one or
more markers predictable for salt sensitivity. The haptoglobin
phenotype [4] and the red blood cell Li/Na countertransport [5,
6] seem to represent two genetic markers related to hypertension
and salt sensitivity. With regard to the neuroendocrine systems
regulating renal sodium handling, a low renin status [2, 3] and a
low urinary dopamine/dopa ratio [7] have been already related to
salt sensitivity in human essential hypertension.
In this context, Bonner et al [8] have recently suggested that a
low kallikrein excretion might determine the salt sensitivity of
blood pressure in normotensives. Because the method used by
Bonner et al [8] is able to discriminate active from inactive
kallikrein in human urine [9, 10], these data seem to be very
interesting. In fact, the behavior of urinary kallikrein strongly
aggregates in families [11]. Moreover, a reduced excretion of
active kallikrein is combined with the highest prevalence of
familial hypertension [11]. Taken together, these data suggest that
a low urinary excretion of active kallikrein could represent an
inheritable phenotype [11], implicated in the pathogenesis of
essential hypertension in subjects sensitive to an "inappropriate"
NaCI intake. According to this hypothesis, an increased blood
pressure response to changes in dietary NaCI intake should be
observed in essential hypertensive patients having a reduced
excretion of active kallikrein. Nevertheless, although active but
not inactive kallikrein excretion is often decreased in essential
hypertensive patients [9, 10, 12] no studies have been carried out
on the role of active kallikrein in determining the individual
response to changes in dietary NaCI intake.
This randomized cross-over double-blind study was planned to
investigate the relationship between the urinary excretion of
active kallikrein, as evaluated on a normal NaCl intake, and the
salt sensitivity of blood pressure in essential hypertensive patients.
Since the behavior of active kallikrein can be strongly influenced
by gender, age, metabolic disturbances, antihypertensive thera-
pies, and renal diseases [12—14], our study was conducted in
never-treated essential hypertensive males with normal renal
function, carbohydrate and lipid metabolisms.
Methods
Patients
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The study was started in 52 never-treated white males, aged
from 35 to 55 years (mean age 44.5 7.7 years), affected by
uncomplicated essential hypertension. All of them were outpa-
tients recruited and followed by our outpatient unit and gave their
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Fig. 1. After a 4-week period on a normal NaCI diet (120 mmol NaG! per day), during which the inclusion criteria and the compliance to the diet were
evaluated, N = 43 essential hypertensive patients were enrolled in the study. Blood samples for plasma renin activity, aldosterone and atrial natriuretic
peptide assays, and urine collections for active kallikrein excretion measurement were taken after further 2 weeks on a normal NaCI intake. Salt
sensitivity was then assessed by evaluating the blood pressure response to changes in dietary NaCl intake, in a randomized double blind cross-over
fashion. During the cross-over phase (2 weeks), patients were replaced on a normal NaC1 intake. Throughout the study, patients were given a low NaCl
diet (40 mmol NaCI per day), and changes in NaCl intake were obtained by the use of a daily supplement of 4 identical capsules containing different
amounts of NaCI or placebo.
informed consent. The study was approved by the Ethics Com-
mittee of the Andrea Cesalpino Foundation. Patients were se-
lected according to the following criteria: no smoking or alcohol
habit; body mass index >18 and <25 kg/rn2; diastolic blood
pressure (DBP) between 95 mm Hg and 114 mm Hg in five visits
performed at one week intervals (Fig. 1); serum creatinine <100
imoI/liter; absence of proteinuria and microalbuminuria <20
g/min on three 24-hour urine collections performed at one week
intervals. All patients had normal renal function as resulted from
both 99mTc diethylenetriamine pentaacetic acid and [1311]o-iodo-
hyppurate scintirenographies. Renal ultrasound evaluation was
also normal in all patients. In order to avoid the influence of
possible diabetes-related renal damage, the presence of a normal
glucose tolerance was proven by the following criteria: fasting
glucose levels <6.5 mmol/liter, fructosamine levels <285 mol/
liter, absence of glycosuria, normal plasma glucose response to
orally administered glucose (75 g). The patients who showed
fasting insulin levels >110 pmol/liter or abnormal insulin response
to orally administered glucose (75 g) were excluded from this
study. All patients had normal levels of plasma cholesterol and
triglycerides (that is, plasma cholesterol <5 and >3.5 mmol/liter;
plasma triglycerides <2 and >1.0 mmol/liter). All patients had no
cardiovascular alterations as evaluated on the basis of clinical and
ultrasound studies. The secondary forms of hypertension were
excluded by clinical and laboratory assessments.
In all patients, a family history of hypertension was evaluated
using a questionnaire and by contacting each primary care physi-
cian as previously described [15]. In brief, at the first visit each
patient was required to answer standard questions. During the
following visits, interviews were also made with patients' wives and
children, if possible. At least, primary care physician was asked to
give final confirmation to resulting family history. A positive
history of hypertension was defined as the presence of one or
more first-degree relatives affected by essential hypertension
before the age of 55 years. Prescribed antihypertensive medica-
tions was considered sufficient to classify a relative as hyperten-
sive. All the family history information was taken by researchers
who were unaware of the study design, purpose, and results.
Study design
At first, all the eligible patients were seen at five screening visits,
performed at one week intervals, in which exclusions were made
for blood pressure and the above cited criteria (Fig. 1). During
this phase, the recruited patients (N =52) were on a normal NaCl
intake (120 mmol NaCl per day). All patients were advised to
drink 2.0 liters water per day. A staff of nutritionists gave written
instructions and detailed information to each patient on the way
to cook without added NaCl. To achieve the normal NaCl intake,
NaCI was added to a standard diet (containing 40 mmol NaCl and
60 mmol K) by means of capsules. In particular, patients took
four capsules per day (each capsule containing 20 mmol NaC1).
To simulate as closely as possible the absorption of salt with food,
according to the Italian habit patients were advised to consume
two capsules at lunch and two at dinner. Adherence to the diet
was assessed using 24 hour urine collections of the last three
consecutive days of each week, Participants were instructed by our
medical staff on how to collect the 24 hour urine. Average 24 hour
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Na excretion was required to be between 80 and 130 mmollday.
Five patients were found not compliant and were excluded from
the study. Moreover, three patients with a DBP <95 mm Hg and
one patient with a DBP >114 mm Hg were also screened out.
Therefore, of the initial cohort of 52 patients, only 43 were
enrolled and continued the normal NaCI intake for further two
weeks (Fig. 1). After this period, during which the compliance to
the diet was assessed as described above, blood samples for
plasma renin activity (PRA), aldosterone (PAC), and atrial
natriuretic peptide (ANP) assays were taken after one hour in the
supine position. On the same day of blood sampling for PRA,
PAC and ANP measurements, the last 24-hour urine collection
was used to evaluate the total amount of urinary active kallikrein
excretion (Fig. 1). Then, patients entered the following phase of
the study.
Salt sensitivity assessment
After blood and urine samplings, patients were randomly,
double-blindly assigned to a high (240 mmol NaCI per day) or a
low (40 mmol NaC1 per day) NaC1 intake in a cross-over fashion
(Fig. 1), that is, 21 patients received a high NaCI intake for two
weeks, then entered a two-week period of normal NaC1 intake and
ended with a two-week period on low NaCI diet, while the
remaining 22 patients were admitted in the contrary sequence.
Changes in dietary NaCI intake were obtained by the administra-
tion of identical capsules (4 capsules per day as described above).
In the case of high NaCI intake, each capsule contained 50 mmol
NaCI. During the low NaC1 intake, each capsule contained
placebo (dextrose).
Throughout the salt sensitivity assessment phase, adherence to
the diet was controlled by measuring the 24-hour sodium excre-
tion on the last three days of each week. Patients were considered
compliant when 24-hour sodium excretion was between 80 and
130 mmol during the normal sodium intake, >220 mmol during
the high sodium intake and <40 mmol during the low sodium
intake. Two patients were found to be not compliant, and the salt
sensitivity assessment was completed in 41 patients.
During the salt sensitivity assessment, blood pressure was
measured, in double blind, twice a week. Patients were classified
as salt sensitive when a change of 10 mm Hg or more of DBP
occurred after both the periods of low and high sodium intake
(that is, blood pressure decrease under low, and increase under
high sodium intake). Changes in blood pressure were evaluated
considering as baseline blood pressure the measurement taken
after the respective period of two weeks on a normal sodium
intake, After salt sensitivity evaluation, four patients showed an
"indeterminate" response to changes in sodium intake: 3 patients
showed a 10 mm Hg DBP increase after the low sodium diet, but
their blood pressure did not change at all during the high sodium
diet; one patient showed an opposite behavior of blood pressure.
These four patients were not considered in the following Results
section.
Potassium intake
To avoid the influence of dietary potassium on kallikrein
excretion [12—14], potassium intake was never changed during the
entire study (that is, 60 mmol K per day from the first screening
visit to the end of the salt sensitivity assessment). Also in this case,
a correct dietary potassium intake was controlled by evaluating
the urinary K excretion on the same occasion of Na determi-
nations. Potassium excretion was required to be between 40
mmol/24 hr and 60 mmol/24 hr.
Blood pressure and biochemical evaluations
Blood pressure and heart rate were controlled twice a week in
our outpatient unit after 30 minutes in the supine position, in an
air conditioned room (21 to 22°C), by a Riva-Rocci mercury
sphygmomanometer (Zenith, Rome, Italy). As recommended
[16], the arm muscle was relaxed and the forearm supported with
the cubital fossa at the heart level. A cuff of suitable size was used
in each case. Systolic blood pressure (SBP) was taken at Korot-
koff's phase I, DBP was taken at Korotkoff's phase V [16]. The
first measurement of blood pressure and heart rate was excluded,
and the average of the following three measurements, taken at
three minute intervals, was considered.
Blood samples for PRA, PAC, ANP, serum Na and K were
withdrawn with the patients in the supine position, after blood
pressure measurement, from an antecubital vein. All the above
determinations were made when each patient was on a normal
NaCI intake (Fig. 1). Plasma samples were immediately stored at
—80°C. All the assays were performed no later than three days
after storage. Plasma ANP was assayed as described elsewhere
[15]. Briefly, ANP was previously extracted from plasma by
Amprep C-18 columns (Amersham Laboratories, Amersham,
Buckinghamshire, UK) activated with 5 ml methanol and 10 ml
distilled water. Each column was loaded with 2.5 ml acidified
plasma. The eluate was collected in 2 ml ethanol, dried under
vacuum, reconstituted in 1 ml phosphate buffer solution (pH 7.4,
Sigma Chemical Co., St. Louis, Missouri, USA) and measured by
radioimmunoassay with a commercially available human-ANP
(99-126) radioimmunoassay (Peninsula Laboratories, Belmont,
California, USA). Synthetic human-ANP (99-126) was used as
standard. Mean recovery in this study was 85%, inter- and
intra-assay variations were less than 10%. PRA and PAC were
assayed by commercially available RIA kits (Sorin Biomedica
S.p.A., Vercelli, Italy). The other laboratory measurements were
performed by standard laboratory methods.
The 24-hour urinary excretion of active kallikrein was measured
in fresh urine by the chromogenic substrate S-2266 (Kabi Diag-
nostica, Molndal, Sweden) according to the method of Amundsen
et al [17]. Aprotinine was used to prevent non-specific hydrolysis
of the substrate. The chromogenic method was preferred to
radioimmunoassay since the latter does not discriminate active
from inactive kallikrein, and only the active form of kallikrein
seems to be reduced in hypertensives [9, 10, 12]. As for PRA, PAC
and ANP assays, active kallikrein excretion was also evaluated in
each patient at the end of the first period on a normal NaC1 intake
(before the assessment of salt sensitivity; Fig. 1).
Statistical methods
The statistical evaluation was performed by a PC Olivetti M-380
XP1 (Olivetti, Ivrea, Italy). The statistical software SPSS (SPSS
Inc. Chicago, Illinois, USA) was used. To evaluate intragroup
statistical significances we used the paired Student's (-test and
ANOVA for repeated measures; to establish differences between
groups we used unpaired Student's (-test and one way analysis of
variance with Bonferroni and Student-Newman-Keuls tests. Lin-
ear regression and correlation were used to evaluate the relation-
ship between two variables. 2 analysis was used for comparison of
descriptive parameters.
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Table 1. General characteristics of the study population
Salt
resistant
hypertensives
Salt
sensitive
hypertensives
Number 18 19
Sex M M
Age years 43.5 4.7 43.0 4.6
Family history of hypertension 6/12 13/6
(yes/no)
BMI kg/rn2 23.0 0.8 23.6 0.5
SBP mm Hg 160.8 6.1 162.1 7.8
DBP mm Hg 106.1 4.7 106.7 4.3
Heart rate beats per mm 72.3 8.7 73.1 8.2
Serum creatinine pmoi/iiter 80.3 5.3 78.3 6.6
Blood urea mmol/iiter 12.5 2.7 11.3 3.1
Serum cholesterol mmoi/liter 4.51 0.41 4.47 0.50
Serum triglycerides mmol/liter 1.48 0.44 1.53 0.42
Creatinine clearance mi/second 1.61 0.30 1.58 0.41
Serum Na mmol/iiter 140.5 3.8 139.6 3.0
Serum K mmoi/iiter 4.35 0.31 4.33 0.24
Fasting plasma insulin pmoi/liter 93.2 12.6 97.8 9.0
Fasting blood glucose mmoi/liter 5.32 0.71 5.75 0.32
Abbreviations are: BMI, body mass index; SBP, systolic blood pressure;
DBP, diatolic blood pressure.
Statistical significance was considered for P values <0.05. All
results are given as mean SD.
Results
When all patients were considered (N = 37, mean age 43.3
4.7 years) during the normal NaC1 intake, SBP and DBP were
161.5 7.2 mm Hg and 106.5 5.1 mm Hg, respectively. Urinary
Na excretion was 108.7 10.4 mmol/24 hr, while urinary K
excretion was 45.8 7.4 mmol/24 hr. Plasma PRA and PAC levels
were 0.29 0.20 ng/liter/second and 272.2 76.5 pmol/liter,
respectively. Plasma ANP was 15.3 4.8 fmol/ml. Urinary
kallikrein excretion was 0.90 0.41 U/24 hr.
At the end of salt sensitivity evaluation, 19 patients (mean age
43.0 4.6 years) were salt sensitive and 18 patients (mean age
43.5 4.7 years) were found to be salt resistant.
Salt sensitive group
The general characteristics of this group are given in Table 1;
blood pressure variations on each diet are given in Table 2. As
shown, SBP significantly increased with high and decreased with
low NaCl diet (P < 0.0001 vs. normal NaCI diet SBP). Also DBP
significantly changed after both high and low salt diet (P < 0.0001
vs. normal NaCI diet DBP). Comparison of the low versus the
high NaCI diet showed a statistically significant difference for both
SBP and DBP (P < 0.0001). Individual blood pressure data for
each diet are given in Figure 2A.
Urinary Na excretion was 110.0 8.4 mmol/24 hr after the
normal sodium diet, 228,8 9.1 mmol/24 hr (P < 0.0001) after
the high sodium diet and 30.5 8.2 mmol/24 hr (P < 0.000 1) after
the low sodium diet. Urinary volume was 1574 106 ml/24 hr at
the end of the normal NaCI intake, decreased to 1445 96 ml/24
hr (P < 0.0001) after the low NaCl diet and increased to 1795
125 ml/24 hr (P < 0.0001) after the high NaCl diet, Body weight
was 80.3 4.5 kg after the normal NaCI diet, increased to 81.9
3.8 kg after the high NaC1 diet, and decreased to 79.0 4.1 kg at
the end of the low NaCI intake period (P < 0.03 vs. high NaC1
diet).
As cited above, PRA, PAC, ANP and kallikrein determinations
were performed after a prolonged period of normal NaC1 intake
(that is, before the assessment of salt sensitivity; Fig. 1). As shown
in Table 3, in this condition PRA levels were 0.25 0.15
ng/liter/second, PAC levels were 268.4 81.9 pmol/liter, and
ANP levels were 17.4 5.5 fmol/ml. Urinary kallikrein excretion
resulted of 0,51 0.36 U/24 hr. The urinary excretion of active
kallikrein and plasma ANP levels resulted in an inverse correla-
tion (r =
—0.691, P < 0.001; Fig. 3).
Salt resistant group
The general characteristics of this group are shown in Table 1.
Neither the high nor the low salt diet induced significant changes
in both SBP and DBP (Table 2). Individual data for blood
pressure behavior during different NaCI diet are given in Figure
2B.
Also, body weight was slightly altered by changes in dietary
NaC1 intake, resulting at 79.5 4.1 kg after the normal NaCl diet,
79.7 3.8 kg after the high NaCI diet and 79.1 3.6 kg at the end
of the low NaCI diet (NS).
Urinary Na excretion was 107.4 11.6 mmol/24 hr on a
normal, 230.6 10.1 mmol/24 hr on a high (P < 0.0001) and 28.4
10.2 mmol/24 hr on a low NaCI intake (P < 0.0001). Urinary
volume was 1538 124 ml/24 hr after the normal, 1356 98
ml/24 hr (P < 0.0001) after the low, and 1886 121 ml/24 hr after
the high NaCI diet (P < 0.0001).
In these cases, PRA, PAC, ANP and active kallikrein measure-
ments were also made when patients were on a normal NaC1
intake (Fig. 1). As shown in Table 3, PRA levels were 0.34 0.25
ng!liter/second, PAC were 276.1 71.1 pmol/liter and ANP levels
were 13.2 4.2 fmol/ml. Urinary kallikrein excretion was 1.28
0.48 U/24 hr. At variance from salt sensitive patients, plasma ANP
and urinary kallikrein excretion were not correlated in the salt
resistant group.
Intergroup comparison
No differences were found between salt resistant and salt
sensitive patients in regard to baseline blood pressure, PRA and
PAC levels. On the contrary, ANP levels were significantly higher
(P < 0.02) in salt sensitive than in salt resistant patients (Table 3).
Moreover, as compared to salt resistant patients, the salt sensitive
ones were characterized by lower values of urinary kallikrein
excretion (P < 0.0001; Table 3). Interestingly, in a scatterplot of
the urinary kallikrein values for each patient divided according to
the salt sensitivity or resistance of blood pressure, two overlapping
but clearly distinguishable bands were observable (Fig. 4). In
particular, urinary active kallikrein levels <0.50 U/24 hr were
present in 10 of 19 salt sensitive and 0 of 18 salt resistant patients,
while 13 of 18 salt resistant and 0 of 19 salt sensitive patients had
kallikrein levels >1.20 U/24 hr. This peculiar behavior is very
close to that reported for two other markers of salt sensitivity, the
Li/Na countertransport and the haptoglobin phenotype [4—6].
Even more interesting, 8 of 10 salt sensitive patients with an active
kallikrein excretion <0.50 U/24 hr had a positive family history of
hypertension, whereas among the 13 salt resistant patients who
had an active kallikrein excretion >1.20 U/24 hr only three had
hypertensive first-degree relatives. On the other hand, hyperten-
sive heredity showed a similar prevalence among patients of both
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Table 2. Blood pressure response to low and high salt intake in salt sensitive and salt resistant hypertensive patients
Salt resistant hypertensives (N = 18) Salt sensitive hypertensives (N = 19)
Normal Normal
NaCI Low NaCI High NaCI NaCI Low NaCI High NaCI
SBP mm Hg
DBP mm Hg
160.8 6.1
106.1 4.7
160.8 4.6c
106.4 4.8c
161.9 7.3"
106.9 5,9C
162.1 7.8
106.7 4.3
148 7,5I3
95.0 3.3'
168.7 8.o
116.9 3.8a
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure.
a P C 0.0001 low vs. normal NaCI intake and high vs. normal NaCI intake in salt sensitive group
5p < 0,0001 low vs. high NaCl intake in salt sensitive group
P C 0.0001 SBP in salt sensitive hypertensives on a low NaCI intake vs. corresponding SBP in salt resistant hypertensives; DBP in salt sensitive
hypertensives on a low NaCI intake vs. corresponding DBP in salt resistant hypertensives; DBP in salt sensitive hypertensives on a high NaCI intake vs.
corresponding DBP in salt resistant hypertensives
"P C 0.02 SBP in salt sensitive hypertensives on a high NaCl intake vs. corresponding SBP in salt resistant hypertensives
groups who had overlapping values of kallikrein (that is, urinary
active kallikrein >0.50 U/24 hr and <1.20 U/24 hr), being present
in 5 of 9 salt sensitive and 3 of 5 salt resistant hypertensives.
Discussion
Although several lines of evidence have indicated a link be-
tween dietary sodium intake and blood pressure, there is a
considerable controversy about the influence of dietary sodium on
the prevention and/or treatment of hypertension.
To explain the heterogeneity of the blood pressure response to
changes in sodium intake different studies focused their attention
to the renal function [18], the renin-angiotensin-aldosterone
system [19], the urinary dopa/dopamine ratio [7], and racial [20,
21], ethnic [21], familial [22], environmental [23] or genetic factors
[22].
A popular hypothesis suggests that selected environmental
factors, such as an "inappropriate" NaCI intake, may lead to
hypertension in subjects with a genetic susceptibility [24]. Accord-
ing to this hypothesis, two genetic markers related to salt sensi-
tivity have already been demonstrated: the haptoglobin phenotype
[4] and the erythrocyte LiVNa countertransport [5, 6]. With
regard to the kallikrein-kinin system, a low urinary excretion of
kallikrein has recently been indicated as a determinant of salt
sensitivity in normotensives [8]. Indeed, only those subjects with a
low kallikrein excretion at baseline reported a significant increase
in blood pressure when fed a high sodium diet [8]. Unfortunately,
the behavior of urinary kallikrein was not studied in hypertensives
and in subjects with a positive family history of hypertension [8].
This fact induced us to evaluate the influence of urinary active
kallikrein excretion on the blood pressure response to changes in
dietary NaCI intake in essential hypertensive patients with and
without a family history of essential hypertension.
As is already known, there is no general agreement about the
assessment of salt sensitivity. Some researchers evaluated this
characteristic by means of acute stimulation [25, 26], while others
used long-term study protocols [26]. In order to eliminate stress
factor influence, we chose a long-term study. Furthermore, to
avoid other confounding factors, the study was performed accord-
ing to a randomized, cross-over, double blind design. Each patient
followed a high (240 mmol NaCl per day) and a low (40 mmol
NaCI per day) sodium diet for two weeks, according to a
randomized sequence (Fig. 1). The different diet periods were
performed after two weeks on a normal (120 mmol NaCI per day)
NaCl intake. Moreover, NaCl was given in capsules, previously
prepared by another staff of researchers. Each patient took four
capsules per day, but neither the physician nor the patient knew
the capsule's contents. In this manner it was possible to assure the
absolute double blindness. Moreover, the adherence of each
patient to the different diets was carefully controlled by measuring
the 24-hour urinary NaCI excretion.
As regard to salt sensitivity definition, we have arbitrarily
chosen a variation of 10 mm Hg for DBP to be observed during
both the high and the low NaCI intake (that is, DBP increase
during the high NaC1 diet and DBP decrease during the low NaC1
diet). We chose this definition because the evaluation of blood
pressure sensitivity after a single change in dietary NaCl intake
can lead to misclassification of the patients [26, 27]. Moreover,
according to previous studies on other determinants of salt
sensitivity [4—6, 8], active kallikrein excretion was measured after
the achievement of sodium balance (before the assessment of salt
sensitivity, when each patient was on a normal NaCI intake) [28,
29].
In a similar way, both the high and the low NaCI diets were
given to each patient for a period sufficient to achieve sodium
balance [28, 29] and started from the same baseline diet (that is,
normal NaC1 intake = 120 mmol NaCl per day for 14 days; Fig. 1).
Moreover, to eliminate the influence of other confounding factors
such as gender [30], race [20, 21], body weight [31], and glucose
tolerance [32], we decided to study only white hypertensive males
with normal body weight and glucose tolerance. To avoid the
influence of potassium intake on urinary kallikrein excretion
[12—14], throughout the study potassium intake remained unvar-
ied, and was periodically checked by evaluating urinary K
excretion.
Therefore, we think our data were not biased by any of the
confounding factors that can be encountered in similar studies.
Our findings showed that salt sensitive patients, as compared to
salt resistant ones, were characterized by not significantly de-
creased levels of PRA. On the contrary, salt sensitive patients
showed significantly elevated plasma ANP levels and reduced
excretion of active kallikrein compared to salt resistant ones.
Although some reports were unable to describe any relation-
ship between the renin status and salt sensitivity in both hyper-
tensives and normotensives [31], there is a general agreement that
low plasma renin is often combined with an enhanced blood
pressure sensitivity to NaC1 intake [reviewed in 2]. Weinberger et
al [3], for instance, reported a 68% prevalence of salt sensitivity in
low renin hypertensives. However, the reasons leading to the lack
of statistically significant differences in PRA levels between the
salt resistant and the salt sensitive group could be related to
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Fig. 2. Individual behavior of systolic and
diastolic blood pressure for salt sensitive (N = 19,
LI, A) and salt resistant (N = 18, U, B) essential
hypertensive patients during different NaCl diets.
Left graphics indicate blood pressure behavior
in salt sensitive (N = 10) and salt resistant
hypertensives (N = 9) following the order:
normal  high  normal  low sodium diet.
Right graphics show blood pressure changes in
the remaining hypertensives (salt sensitive, N =
9; salt resistant, N = 9) who followed the
reverse order. Horizontal bars indicate mean
values.
different events. As is well known, PRA levels vary according to a
normal distribution [33]. Therefore, classification of hypertensives
into renin subgroups is an arbitrary division along a continuous
distribution. Furthermore, the most precise way to discriminate
low from normal-high renin hypertensives is to evaluate PRA
after a prolonged period of low NaC1 intake [34—361. In this study,
we evaluated PRA after a carefully controlled period of normal
NaCI intake, and the PRA evaluation was not repeated on a low
NaCl intake. According to these facts, PRA was not significantly
reduced in our salt sensitive hypertensives.
On the other hand, Williams and Hollenberg recently described
a subset of salt sensitive hypertensives having normal to high
levels of PRA [19, 35, 36]. These patients were defined "non-
modulators" in consequence of their impaired renal and endo-
crine responsiveness to both angiotensin II and saline infusions
and, together with low renin patients, should represent about 50
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Table 3. Hormonal characteristics of the study population
Salt resistant
hypertensives(N=18)
Salt sensitive
hypertensives(N=19)
Plasma renin activity 0.34 0.25 0.25 t 0.15
nglliter/second
Plasma aldosterone pmol!liter 276.1 71.1 268.4 81.9
Plasma atrial natriuretic peptide 13.2 4.2 17.4 5,5a
fmol/ml
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Fig. 3. Correlation between urinary excretion of active kallikrein and plasma
atrial natriuretic peptide in salt sensitive hypertensive males (N 19). r
—0.691; P < 0.001.
to 60% of the total population of hypertensives [35]. In a recent
report [37], we have confirmed the data from Williams and
Hollenberg [19, 35, 36], demonstrating that non-modulators are
about 55% of salt sensitive hypertensives, and low renin ones
about 45%. Moreover, according to Williams and Hollenberg [19,
35, 36] non-modulating plus low renin hypertensives constituted
approximately 60% of the total sample [37]. Therefore, it is not
surprising that a low renin status does not represent a good
predictor of the blood pressure response to changes in dietaiy
NaCI intake.
In the current study, plasma concentrations of ANP were
significantly higher in salt sensitive than in salt resistant patients.
Similar findings have already been demonstrated in salt sensitive
normotensives [38] and hypertensives [39]. As is known, atrial
secretion of ANP appears to be elicited by volume expansion [40].
Therefore, our data suggest that the ability of the kidney to
excrete sodium could be primarily impaired in salt sensitive
hypertensives, resulting in greater NaCl retention and corre-
sponding compensatory increment in plasma ANP levels.
In accordance with this hypothesis, the reduced excretion of
P<0.0001
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Fig. 4. Scatterplots show plasma renin activity levels (A), plasma aErial
natriuretic peptide levels (B), and urinary excretion of active kallikrein (C) in
all hypertensive patients (N = 37, 0) and, separately, in the salt sensitive (N
= 19, 0) and the salt resistant subgroup (N = 18, U). Horizontal bars
indicate mean values.
active kallikrein observed in salt sensitive hypertensives during a
normal NaCl intake (that is, before changes in dietary NaCl
intake) suggests a malfunction of the renal kallikrein-kinin system
as a possible cause for both chronic NaCl retention and blood
pressure sensitivity to changes in dietary NaCl intake. Renal
kallikrein is mainly produced by the distal part of the tubules,
where it acts on locally produced kininogen to generate active
kinins [12—14]. These latter are responsible for several actions,
leading to sodium and potassium loss in pre-urine fluid [12—14].
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Therefore, the presence of an impaired renal sodium excretory
function could be suggested in patients having a reduced produc-
tion of active kallikrein. According to this hypothesis, only salt
sensitive hypertensives reported significant modifications of body
weight during changes in dietary NaCl intake. Moreover, the same
patients showed the highest levels of plasma ANP as well as an
inverse correlation between the latter and the urinary excretion of
active kallikrein. In this context, this correlation has already been
demonstrated by DessI-Fulgheri [41] and us [15] in adult and
young essential hypertensives on a normal NaC1 intake, respec-
tively. In both studies, the blood pressure sensitivity to changes in
dietary NaCI intake were not evaluated. However, we [15] and
DessI-Fulgheri [41] speculated that the increase of plasma ANP in
hypertensives with a low urinary excretion of kallikrein could
represent a compensatory mechanism trying to improve an im-
paired renal NaC1 excretory capability. Although this hypothesis
remains only an intriguing possibility, we think it is now further
supported by the evidence that salt sensitive, but not salt resistant
hypertensives, showed a significant inverse correlation between
plasma ANP and urinary kallikrein excretion. On the other hand,
a possible role for the kallikrein-kinin system in the hypertension
development of salt sensitive hypertensives is also supported by
our recent data [42] showing that kallikrein administration re-
duces blood pressure in salt sensitive but not in salt resistant
hypertensives.
According to this hypothesis, Berry and co-workers were able to
classify 80% of their study population into groups with a high or
a low kallikrein genotype [11]. Moreover, low kallikrein excretion
segregated in Utah pedigrees as a Mendelian recessive trait, and
both young and adult Utah inhabitants with low urinary kallikrein
excretion had hypertensive first-degree relatives twice as often
than those who had a high urinary kallikrein excretion [11]. In this
study, we showed that salt sensitive hypertensives had the lowest
levels of urinary kallikrein (Fig. 4) and the highest prevalence of
hypertensive heredity (Table 1). Even more interesting, a positive
family history of hypertension recurred in 80% of salt sensitive
hypertensives having an excretion of active kallikrein <0.50 U/24
hr, while hypertensive heredity was present only in 23% salt
resistant patients who excreted more than 1.20 U/24 hr. This fact
seems to be very intriguing, since all salt sensitive patients
excreted less than 1.20 U/24 hr of active kallikrein and none of the
salt resistant hypertensives had an excretion of active kallikrein
<0.50 U/24 hr. Therefore, these cut-off values were able to
identify more than 60% of the total hypertensive population as
sensitive or resistant to changes in dietary NaC1 intake, showing a
better predictivity than the Li/Na countertransport and the
haptoglobin phenotype that is, of the two previously known
markers of salt sensitivity [4—6]. Moreover, the presence of a low
kallikrein excretion in patients having a very high prevalence of
familial hypertension could support the hypothesis that salt intake
might represent one of the environmental factors contributing to
hypertension development in subjects having a particular genetic
susceptibility [11, 22, 24]. However, further studies in Utah
pedigrees suggested the presence of elevated LDL, low HDL
levels, hyperinsulinemia and glucose intolerance in hypertensive
relatives of normotensive individuals, leading to the definition of
"familial dyslipidemic hypertension" [22—24, 43]. These findings
could make the Utah subjects different from our patients, since
none of the latter suffered from metabolic abnormalities.
In conclusion, our data indicate that reduced urinary active
kallikrein and increased plasma ANP levels are present in salt
sensitive hypertensives compared to salt resistant ones. We spec-
ulate that the reduction of active kallikrein could play a patho-
genic role in the development of hypertension during an "inap-
propriate" salt intake, while the increase in plasma ANP levels
could represent a compensatory mechanism to the impaired renal
sodium excretory capability. In this regard, our data propose
urinary kallikrein excretion as a marker for salt sensitivity, as the
red blood cell Li/Na countertransport [5, 6] and the haptoglo-
bin phenotype [4]. The excretion of active kallikrein could be used
to predict the salt sensitivity of blood pressure, improving the
efficacy of salt restriction as a non-pharmacological therapy of
essential hypertension.
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